|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||66.40 - 81.12|
|52 Week Range||66.40 - 331.68|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 28, 2022 - Mar. 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||270.00|
The bullish case for owning COVID-19 vaccine makers is weakening as much of the world throws in the towel on trying to curb the spread of the coronavirus.
Novavax (NASDAQ: NVAX) is arriving more than a year after market leaders Pfizer and Moderna to the coronavirus vaccine finish line. Novavax soared 2,700% in 2020. As of today, Novavax's vaccine has won authorization from more than 30 countries.
Dr. Owais Durrani, Emergency Medicine Physician, joins Yahoo Finance Live to discuss including the booster shot in definitions of being fully vaccinated, monitoring and testing for potential COVID symptoms, transmissibility in hospitals for non-COVID patients, and the outlook on variant case numbers.